{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T17:24:10Z","timestamp":1779384250174,"version":"3.53.1"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Flurbiprofen, as a widely used nonsteroidal anti-inflammatory drug (NSAID), is commonly employed to relieve mild to moderate pain and inflammation. Understanding its adverse reactions in real-world usage is of significant importance.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Reports of all adverse drug events (ADEs) related to flurbiprofen were extracted from the FAERS database, covering the period from Q1 2004 to Q3 2024. These reports were standardized and analyzed using various signal quantification techniques, including Reporting Odds Ratios (ROR), Proportional Reporting Ratios (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinkage (MGPS). Finally, the association between flurbiprofen and ADEs as well as clinical medical events was assessed.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 275 cases from the target population were identified in the FAERS database, with 788 instances of adverse events (AEs) occurring across 46 organ systems. We identified not only some common adverse reactions listed in the drug\u2019s package insert, such as acute kidney injury, nausea and vomiting, and facial edema, but also significant signals that were not mentioned in the package insert, including Dysphonia, Drug abuse, and Pancreatitis acute. The median time to onset of flurbiprofen-related AEs was 1 day (interquartile range [IQR] 0\u20135 days), with most AEs occurring within the first month of flurbiprofen use.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>This study confirmed some common adverse reactions listed in the flurbiprofen drug package insert and identified significant unexpected adverse reactions. These findings can assist clinicians in conducting more comprehensive clinical monitoring when using the drug, thereby ensuring patient safety during treatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0329636","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T17:24:14Z","timestamp":1754501054000},"page":"e0329636","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["In-depth summary of adverse events associated with Flurbiprofen: A real-world pharmacovigilance study from 2004 to 2024 using the FAERS database"],"prefix":"10.1371","volume":"20","author":[{"given":"Chengkai","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1589-4513","authenticated-orcid":true,"given":"Huaxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"issue":"6","key":"pone.0329636.ref001","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40272-022-00514-1","article-title":"Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years","volume":"24","author":"VC Ziesenitz","year":"2022","journal-title":"Paediatr Drugs"},{"key":"pone.0329636.ref002","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/B978-0-12-397220-0.00004-0","article-title":"Flurbiprofen","volume":"37","author":"AA Abdel-Aziz","year":"2012","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"issue":"11","key":"pone.0329636.ref003","first-page":"1705","article-title":"Recategorization of Non-Aspirin Nonsteroidal Anti-inflammatory Drugs According to Clinical Relevance: Abandoning the Traditional NSAID Terminology","volume":"37","author":"K Bonnesen","year":"2021","journal-title":"Can J Cardiol"},{"key":"pone.0329636.ref004","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1107185","article-title":"A systematic review of flurbiprofen 8.75\u2009mg dose and risk of adverse events (excluding haemorrhagic) resulting from drug-drug interactions","volume":"15","author":"A Evans","year":"2024","journal-title":"Front Pharmacol"},{"key":"pone.0329636.ref005","doi-asserted-by":"crossref","first-page":"862508","DOI":"10.3389\/fphar.2022.862508","article-title":"Post-marketing safety concerns with secukinumab: A disproportionality analysis of the FDA adverse event reporting system","volume":"13","author":"Y Shu","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"pone.0329636.ref006","doi-asserted-by":"crossref","first-page":"20601","DOI":"10.1038\/s41598-022-23726-4","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib","volume":"12","author":"M Guo","year":"2022","journal-title":"Sci Rep"},{"key":"pone.0329636.ref007","doi-asserted-by":"crossref","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","article-title":"Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database","volume":"15","author":"F Zou","year":"2024","journal-title":"Front Pharmacol"},{"issue":"4","key":"pone.0329636.ref008","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/andr.13533","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil","volume":"12","author":"Y Wang","year":"2024","journal-title":"Andrology"},{"issue":"5","key":"pone.0329636.ref009","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5582\/ddt.2022.01052","article-title":"Comparison of efficacy and safety in the combination therapies of duloxetine and S-flurbiprofen plaster, and of duloxetine and conventional NSAIDs for chronic pain in patients with osteoarthritis (OASIS DUAL study)","volume":"16","author":"K Koyama","year":"2022","journal-title":"Drug Discov Ther"},{"key":"pone.0329636.ref010","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jss.2019.11.032","article-title":"Efficacy of flurbiprofen for postoperative pain in Chinese surgical patients: a meta-analysis","volume":"252","author":"M Sun","year":"2020","journal-title":"J Surg Res"},{"key":"pone.0329636.ref011","doi-asserted-by":"crossref","first-page":"1123734","DOI":"10.3389\/fphar.2023.1123734","article-title":"Flurbiprofen inhibits heme induced NLRP3 inflammasome in Berkeley sickle cell disease mice","volume":"14","author":"D Kour","year":"2023","journal-title":"Front Pharmacol"},{"key":"pone.0329636.ref012","doi-asserted-by":"crossref","first-page":"216","DOI":"10.14740\/gr658w","article-title":"Cross-Sectional Study for Prevalence of Non-Steroidal Anti-Inflammatory Drug-Induced Gastrointestinal, Cardiac and Renal Complications in India: Interim Report","volume":"8","author":"S Chatterjee","year":"2015","journal-title":"Gastroenterology Res"},{"issue":"7","key":"pone.0329636.ref013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0200023","article-title":"The prevalence of endoscopic gastric mucosal damage in patients with rheumatoid arthritis","volume":"13","author":"S Tsujimoto","year":"2018","journal-title":"PLoS One"},{"issue":"5","key":"pone.0329636.ref014","first-page":"218","article-title":"Frequency of NSAID induced peptic ulcer disease","volume":"56","author":"S Hamid","year":"2006","journal-title":"J Pak Med Assoc"},{"key":"pone.0329636.ref015","doi-asserted-by":"crossref","first-page":"258209","DOI":"10.1155\/2013\/258209","article-title":"Current perspectives in NSAID-induced gastropathy","volume":"2013","author":"M Sinha","year":"2013","journal-title":"Mediators Inflamm"},{"issue":"4","key":"pone.0329636.ref016","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejim.2015.03.008","article-title":"Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies","volume":"26","author":"P Ungprasert","year":"2015","journal-title":"Eur J Intern Med"},{"issue":"1","key":"pone.0329636.ref017","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1590\/2175-8239-jbn-2018-0107","article-title":"Pathophysiological aspects of nephropathy caused by non-steroidal anti-inflammatory drugs","volume":"41","author":"GNC Lucas","year":"2019","journal-title":"J Bras Nefrol"},{"key":"pone.0329636.ref018","article-title":"Renal injury in NSAIDs: a real-world analysis based on the FAERS database","author":"H Xu","year":"2024","journal-title":"Int Urol Nephrol"},{"key":"pone.0329636.ref019","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fped.2019.00520","article-title":"The Invisible Threat of Non-steroidal Anti-inflammatory Drugs for Kidneys","volume":"7","author":"S Clav\u00e9","year":"2019","journal-title":"Front Pediatr"},{"key":"pone.0329636.ref020","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3389\/fped.2019.00517","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) systemic use: the risk of renal failure","volume":"7","author":"A Bensman","year":"2020","journal-title":"Front Pediatr"},{"issue":"4","key":"pone.0329636.ref021","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.pop.2014.09.001","article-title":"Nonsteroidal antiinflammatory drugs, cyclooxygenase-2, and the kidneys","volume":"41","author":"S Rahman","year":"2014","journal-title":"Prim Care"},{"issue":"11","key":"pone.0329636.ref022","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1056\/NEJMra1712125","article-title":"Aspirin-Exacerbated Respiratory Disease","volume":"379","author":"AA White","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0329636.ref023","article-title":"Aspirin exacerbated respiratory disease: epidemiology, pathophysiology, and management","volume":"7","author":"KL Li","year":"2019","journal-title":"Med Sci"},{"issue":"4","key":"pone.0329636.ref024","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/infdis\/jiw603","article-title":"Acute respiratory infection and use of nonsteroidal anti-inflammatory drugs on risk of acute myocardial infarction: a nationwide case-crossover study","volume":"215","author":"YC Wen","year":"2017","journal-title":"J Infect Dis"},{"issue":"3","key":"pone.0329636.ref025","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/all.14032","article-title":"Progress in understanding hypersensitivity reactions to nonsteroidal anti-inflammatory drugs","volume":"75","author":"I Do\u00f1a","year":"2020","journal-title":"Allergy"},{"issue":"3","key":"pone.0329636.ref026","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.iac.2017.04.006","article-title":"Angiotensin-converting enzyme inhibitor and other drug-associated angioedema","volume":"37","author":"C Stone","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"issue":"6","key":"pone.0329636.ref027","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.jaip.2021.04.023","article-title":"Triggers of Exacerbation in Chronic Urticaria and Recurrent Angioedema-Prevalence and Relevance","volume":"9","author":"AS Grumach","year":"2021","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0329636","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T17:24:19Z","timestamp":1754501059000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0329636"}},"subtitle":[],"editor":[{"given":"Mohammed","family":"Misbah Ul Haq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0329636","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]}}}